Product Name: CAMK4 (202-) pT204+pY207
Product Number: PE-04ASC01
Size: | 200 µg | | Price: | 15.00 |
| 1 mg | | $US | 30.00 |
Peptide Name: CAMK4 (202-210) pT204+pY207
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. T204 and Y207 phosphorylation are predicted to be inhibitory.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CG-pT-PG-pY-CAP
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1026.9 Da
Peptide Purity Percent after Synthesis and Purification: >50
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Storage Stability: stable
Scientific Background: CaMK4 is a protein-serine/threonine kinase of the CAMK group and CAMK1 family. It is a calcium/calmodulin-dependent protein kinase. This kinase is monomeric in structure and occurs in two isoforms generated by alternative splcing from the same gene. It is implicated in immune response, inflammation, memory consolidation, positive selection of T lymphocytes, cytokine production, regulation in neurons and male germ cells, survival and differentiation of osteoblasts and dendritic cells. It is highly expressed in rat tissues such as the forebrain, lymphocytes, spleen, testis, and thymus. Immunohistochemical studies have demonstrated a nuclear localization of the transiently expressed CaMK4. The cytoskeletal and perinuclear localization of inducible CaMK4 implies that the kinase may be a modulator of cell shape and/or motility and/or activity of a cytoskeleton-associated nuclear factor. It regulates many transcription activators such as CREB1, and JUN. It can also activate MAPK pathway through phosphorylation of ELK1 and ATF2. Mutations (S12A, S13A, T57A+K58E, K75E, T200A) are mostly result in loss of phosphotransferase activity or loss of activation by the upstream kinases CaMKK1 or CaMKK2. Some mutations (S189A, H309D+M310E+T312D+F320D+N321D+) lead to a constitutively active form.
![kinexus](/Ads/Ad02.jpg)